Your browser doesn't support javascript.
loading
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma.
Nikkarinen, Anna; Lokhande, Lavanya; Amini, Rose-Marie; Jerkeman, Mats; Porwit, Anna; Molin, Daniel; Enblad, Gunilla; Kolstad, Arne; Räty, Riikka; Hutchings, Martin; Weibull, Caroline E; Hollander, Peter; Ek, Sara; Glimelius, Ingrid.
Afiliación
  • Nikkarinen A; Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden.
  • Lokhande L; Department of Immunotechnology, Lund University, Lund, Sweden.
  • Amini RM; Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden.
  • Jerkeman M; Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden.
  • Porwit A; Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden.
  • Molin D; Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden.
  • Enblad G; Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden.
  • Kolstad A; Department of Oncology, Innlandet Hospital Trust Division Gjøvik, Lillehammer, Norway.
  • Räty R; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Hutchings M; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
  • Weibull CE; Division of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
  • Hollander P; Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden.
  • Ek S; Department of Immunotechnology, Lund University, Lund, Sweden.
  • Glimelius I; Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden.
Blood Adv ; 7(18): 5304-5313, 2023 09 26.
Article en En | MEDLINE | ID: mdl-37389827

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma de Células del Manto Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma de Células del Manto Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article